Tipifarnib

Tipifarnib (Zarnestra) is a drug that is being investigated in patients 65 years of age and older with newly diagnosed acute myeloid leukemia (AML).

The compound was discovered by and is under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C, with registration number R115777.